Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze ENTA stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate ENTA investment potential.

What is ENTA stock price today?

Get real-time ENTA stock price, historical data, and price charts on Financhill. Track ENTA performance with our advanced analysis tools.

Is ENTA a good investment?

Evaluate ENTA investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy ENTA stock?

To buy ENTA stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of ENTA?

View detailed market capitalization data and company valuation metrics for ENTA on our comprehensive analysis page.

What is the P/E ratio of ENTA?

Use our fundamental analysis tools to view ENTA P/E ratio and compare valuation metrics with industry peers.

What are ENTA earnings?

View ENTA earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Enanta Pharmaceuticals, Inc. 10K Form

Buy

ENTA
Enanta Pharmaceuticals, Inc.

Last Price:

$14.24

Seasonality Move:

-9.41%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-08	10Q	ENTA/Enanta Pharmaceuticals, Inc. Quarterly
2024-02-08	10Q	ENTA/Enanta Pharmaceuticals, Inc. Quarterly
2023-08-08	10Q	ENTA/Enanta Pharmaceuticals, Inc. Quarterly
2023-05-09	10Q	ENTA/Enanta Pharmaceuticals, Inc. Quarterly
2023-02-08	10Q	ENTA/Enanta Pharmaceuticals, Inc. Quarterly
2022-08-08	10Q	ENTA/Enanta Pharmaceuticals, Inc. Quarterly

Receive ENTA News And Ratings

See the #1 stock for the next 7 days that we like better than ENTA

ENTA Financial Statistics

Sales & Book Value

Annual Sales:	$65.3M
Cash Flow:	$-11.8M
Price / Cash Flow:	0
Annual Sales:	$4.36
Price / Book:	3.28

Profitability

EPS (TTM):	-3.20430
Net Income (TTM):	$-71.5M
Gross Margin:	$60.7M
Return on Equity:	-75.15%
Return on Assets:	-22.43%

Enanta Pharmaceuticals, Inc. Earnings Forecast

Key Enanta Pharmaceuticals, Inc. Financial Ratios

The Gross Profit Margin over the past 16 years for ENTA is 92.98%.
The Selling, General & Administrative Expenses for ENTA have been equal to 67.25% of Gross Profit Margin.
The Research & Development expenses have been 163.40% of Revenue.
The Net Earning history of ENTA is -125.36% of Total Revenues.
Per Share Earnings over the last 16 years have been positive in 7 years.

Enanta Pharmaceuticals, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Biotechnology
Sector:	Health Care
Current Symbol:	ENTA
CUSIP:	29251M
Website:	enanta.com

Debt

Debt-to-Equity Ratio:	1.53
Current Ratio:	4.44
Quick Ratio:	4.35

Price-to-Earnings

Trailing P/E Ratio:	0
Forward P/E Ratio:	0

ENTA Technical Analysis vs Fundamental Analysis

Buy

Enanta Pharmaceuticals, Inc. (ENTA) is a Buy

Is Enanta Pharmaceuticals, Inc. a Buy or a Sell?

Enanta Pharmaceuticals, Inc. stock is rated a Buy

The current Enanta Pharmaceuticals, Inc. [ENTA] share price is $14.30. The Score for ENTA is 51, which is 2% above its historic median score of 50, and infers lower risk than normal.